CClinicalTrials.gg
Status unknownNCT02336867FISCLOSEUpdated Sep 22, 2015

Therapeutic Management of Complex Anal Fistulas by Installing a Closure Clip: Multicentre Randomized Controlled Trial

A Phase 2/3 interventional study of Closure clip (OTSC® Proctology) in Complex Anal Fistula, sponsored by University Hospital, Clermont-Ferrand. Status unknown at 1 site in France. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2015-09-22.

Sponsored by University Hospital, Clermont-Ferrand · Phase 2/3, Interventional, and Treatment

The sponsor has not verified this record recently (last verified Sep 2015), so the status shown — last known as Recruiting — may be out of date.
Phase
Phase 2/3
Study type
Interventional
Enrollment
92
Allocation
Randomized
Ages
18 Years to 80 Years
Sex
All
01

Study summary

Anal fistulas are the main etiology of perianal abscesses and suppurations. They are common and generally associated with pain, anal incontinence, impaired quality of life and work incapacity. The therapeutic management of this disease has a double objective: heal the suppuration and preserve the sphincter function. Each year, anal fistulas affect 1 in 10 000 in the normal population, with a difference in prevalence between men and women (1.23 per 10 000 men and 0.56 per 10 000 women). The average age of the patients was 40 years (Simpson et al., 2012).

In about 80% of cases, anal fistulas are secondary to an infection of Hermann and Desfosses' anal glands (cryptogenic or cryptoglandular). Infection of the anal gland can result in an abscess between the internal and external sphincters, which in turn can spread to other parts of the perianal region. The infection can follow many directions from this point in the intersphincteric plan. When the pus reaches the skin, the fistula is formed. Anal fistula therefore has always an intraductal origin, cryptic, with a primary port at this level, and the disregard of which causes the recurrence of the fistula; and usually a secondary port in the skin.

Fistulas are usually divided into two groups. The first group contains fistulas called "simple", which are intersphincteric fistulas or trans-sphincteric involving only the lower third of the sphincter complex. Fistulas usually didn't affect any muscle. The second group contains fistulas called "complex". These are intersphincteric, trans-sphincteric, or even suprasphincteric, extrasphincteric fistulas.

For many years, the treatment of choice was to open the fistula (fistulotomy), but this procedure was associated with a risk of incontinence, the consequences could be potentially devastating. Other surgical treatments include setons, fibrin glue, collagen plugs and advancement flap technique to cover internal opening of the fistula. The success of these therapies remains variable.

The advancement flap technique remains a strategy of choice in the treatment of anal fistulas and particularly in the case of complex fistulas. The success rate of the advancement flap technique remains variable across studies but a recent meta-analysis finds a success rate of around 60%.

A new technique for closing anal fistula is currently in development with the use of a closure clip nitinol (OTSC® Proctology Laboratory: OVESCO and French Distributor: Life Partners). This new technique has been validated in a porcine model of anal fistula, ensuring the safety of the device. A first case was published in a patient with complex anal fistula (high trans-sphincteric). After erosion fistula tract with a special brush, a nitinol clip (OTSC® Proctology) was deposited on the internal opening of the fistula. Eight months after surgery, the fistula was healed and the clip was removed by cutting with special pliers. This technique is currently being broadcast and dozens of patients were treated with this clip without any further scientific validation of the process.

To date, this innovative technique of the closure clip has not yet been assessed in a randomized controlled trial. It is therefore essential to carry out a prospective evaluation in order to determine the effectiveness and safety of this new device in the case of complex anal fistulas.

Read the detailed description

After validation of the inclusion and exclusion criteria, the patients included in this clinical trial will be randomized between the two arms of the study for the closure of the anal fistula:

  • Control group: advancement flap technique Experimental group: closure clip (OTSC® Proctology Laboratory: OVESCO and French Distributor: Life Partners)

Follow up of the patients will be performed until 1 year after the intervention.

02

Conditions studied

  • Complex Anal Fistula

Keywords

  • Complex anal fistula, clip,
03

In context

Rectal Fistula

189 studies on the registry are indexed under Rectal Fistula; 42 are open to participants now.

This study's planned enrollment of 92 is above the median of 68 across 130 interventional studies indexed under Rectal Fistula.

Browse Rectal Fistula studies →

Lead sponsor

University Hospital, Clermont-Ferrand is the lead sponsor of 841 studies on the registry; 178 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • Complex anal fistula (intersphincteric, trans-sphincteric, or even suprasphincteric, extrasphincteric) drained and requiring closing intervention of fistula.
  • Obtaining the patient's written consent
  • Naive patient to any surgical treatment for fistula closure
  • Patient receiving a social security scheme

Exclusion criteria

Exclusion Criteria:

  • \<18 years and> 80 years
  • BMI> 35 kg / m²
  • Rectovaginal or rectourethral fistulas
  • Infections : sepsis, tuberculosis or HIV
  • History of allergy to nickel
  • Cognitive disorders or major disability making it impossible to understand the study and signed an informed consent
  • Already included in another clinical trial patients
  • breastfeeding or pregnancy
  • Legal incapacity (person deprived of liberty or guardianship)
  • Patients not compliant with the criteria of the study
05

Study design

Phase
Phase 2 / Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Investigator)
Enrollment
92 participants (estimated)

Study arms

  • Experimental
    Experimental group

    closure clip (OTSC® Proctology Laboratory: OVESCO and French Distributor: Life Partners)

    Device: Closure clip (OTSC® Proctology)

  • Other
    Control group

    advancement flap technique

    Device: Closure clip (OTSC® Proctology)

Interventions

  • DeviceClosure clip (OTSC® Proctology)
06

What researchers measure

Primary outcomes

  1. Proportion of patients with healed anal fistula

    The diagnosis will be made by the lack of leakage alleged by the patient for at least one month and found on clinical examination

    Time frame: at 3 months after surgery

Secondary outcomes

  1. Anal fistula healing

    Time frame: at 6 months and 1 year

  2. VAS proctologic pain

    Time frame: days 0, 1, 2, 3, 15, 30, 60, 90, 180 and 365

  3. Anal incontinence score (questionnaire Jorge and Wexner)

    Time frame: days 0, 15, 30, 60, 90, 180 and 365

  4. Digestive disorders and quality of life (GIQLI questionnaire)

    Time frame: days 0, 15, 30, 60, 90, 180 and 365

  5. Quality of life (EQ5D Questionnaire)

    Time frame: days 0, 30, 90, 365

07

Study locations

1 of 1 sites recruiting
08

References and documents

Publications

  • Dubois A, Carrier G, Pereira B, Gillet B, Faucheron JL, Pezet D, Balayssac D. Therapeutic management of complex anal fistulas by installing a nitinol closure clip: study protocol of a multicentric randomised controlled trial--FISCLOSE. BMJ Open. 2015 Dec 16;5(12):e009884. doi: 10.1136/bmjopen-2015-009884. PubMed 26674505 ↗
09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Sep 22, 2015, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02336867
Lead sponsor
University Hospital, Clermont-Ferrand
Responsible party
Sponsor
First posted
Jan 13, 2015
Start date
Jan 2015
Primary completion
Jan 2017 (estimated)
Completion
Feb 2017 (estimated)
Last update
Sep 22, 2015

Study contacts

Patrick LACARIN
Contact
placarin@chu-clermontferrand.fr
04 73 75 11 95
Anne DUBOIS
principal investigator · University Hospital, Clermont-Ferrand
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Sep 2015. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion